KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EBITDA (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of EBITDA data on record, last reported at $196.8 million in Q2 2025.

  • For Q2 2025, EBITDA rose 3115.28% year-over-year to $196.8 million; the TTM value through Jun 2025 reached $401.5 million, up 748.43%, while the annual FY2024 figure was $218.1 million, 140.89% up from the prior year.
  • EBITDA reached $196.8 million in Q2 2025 per SRPT's latest filing, up from $161.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $196.8 million in Q2 2025 and bottomed at -$515.5 million in Q1 2023.
  • Average EBITDA over 5 years is -$71.8 million, with a median of -$48.2 million recorded in 2021.
  • Peak YoY movement for EBITDA: tumbled 888.63% in 2021, then surged 3115.28% in 2025.
  • A 5-year view of EBITDA shows it stood at -$122.0 million in 2021, then rose by 11.71% to -$107.7 million in 2022, then skyrocketed by 143.83% to $47.2 million in 2023, then surged by 242.46% to $161.7 million in 2024, then increased by 21.73% to $196.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $196.8 million in Q2 2025, $161.7 million in Q4 2024, and $36.9 million in Q3 2024.